Puma Biotech DEF 14A: Executive Compensation Details
Ticker: PBYI · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, stock-options
TL;DR
Puma Biotech's DEF 14A is out, showing exec stock options and compensation for 2024. Check it for details on Hunt, Ludwig, and others.
AI Summary
Puma Biotechnology, Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock options granted to key executives such as Douglas Hunt, Jeff J. Ludwig, Alvin Wong, Maximo F. Nougues, and Alan H. Auerbach. Specific details regarding the change in fair value of equity awards and vesting dates are provided for the reporting period.
Why It Matters
This filing provides transparency into how Puma Biotechnology compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new financial risks.
Key Players & Entities
- PUMA BIOTECHNOLOGY, INC. (company) — Filer
- Douglas Hunt (person) — Executive
- Jeff J. Ludwig (person) — Executive
- Alvin Wong (person) — Executive
- Maximo F. Nougues (person) — Executive
- Alan H. Auerbach (person) — Executive
- 2024-12-31 (date) — Fiscal Year End
- 20250428 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
Which fiscal year does the executive compensation information primarily cover?
The executive compensation information primarily covers the fiscal year ending December 31, 2024.
Who are some of the key executives whose stock options are detailed in the filing?
Key executives whose stock options are detailed include Douglas Hunt, Jeff J. Ludwig, Alvin Wong, Maximo F. Nougues, and Alan H. Auerbach.
What is the company's standard industrial classification code?
The company's standard industrial classification code is 2834, which corresponds to Pharmaceutical Preparations.
When was the company formerly known as Innovative Acquisitions Corp?
The company was formerly known as Innovative Acquisitions Corp, with a date of name change on June 1, 2007.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 by Douglas Hunt regarding PUMA BIOTECHNOLOGY, INC. (PBYI).